SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--First Patient Dosing in Phase 1b Trial of FPA150
Thu Feb 21, 2019 03:05
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces Participation in Upcoming Investor Conferences
Wed Feb 20, 2019 23:20
WASHINGTON--(BUSINESS WIRE)--The Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research worldwide, applauds the U.S. Food & Drug Administration (FDA) approval of Merck’s pembrolizumab (Keytruda®) in the adjuvant setting for melanoma patients with lymph node involvement following complete lymph node resection. Melanoma, the deadliest skin cancer, is the fifth most common cancer in the U.S. An estimated 9% of new cases have spread to lymph nodes or nearby sites a
Wed Feb 20, 2019 23:10
MONTREAL--(BUSINESS WIRE)--Stem cells, acute liver failure, Morphocell Technologies
Wed Feb 20, 2019 23:06
DANVERS, Mass.--(BUSINESS WIRE)--In einer Entwicklung, die einen Meilenstein bei der wissenschaftlichen Forschung bedeutet, hat Abiomed (NASDAQ: ABMD) in den vergangenen fünf Jahren mehr als 100 Millionen US-Dollar in die klinische Forschung zu Impella-Herzpumpen investiert. Abiomeds Engagement bei der klinischen Forschung wird auf einer neuen Website detailliert vorgestellt, die heute live geschaltet wurde. Die von Abiomed gesponserten Forschungsbemühungen werden durch zwei Jahrzehnte unabhäng
Wed Feb 20, 2019 22:11
RALEIGH, N.C.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/alzheimersdisease?src=hash" target="_blank"gt;#alzheimersdiseaselt;/agt;--Raleigh Neurology Associates, P.A., one of the largest and most respected neurology practices in the nation announces that Mark Ragusa has joined the practice as Director of Clinical Research at its main office in Raleigh, NC. Mark is an accomplished leader in the healthcare entrepreneurial technology industry. As Director of Clinical Research, Mark will...
Wed Feb 20, 2019 21:27
BLOOMINGTON, Ind.--(BUSINESS WIRE)--A recently published multi-center, randomized, controlled trial (RCT) demonstrated higher rates of healing when using OASIS® Wound Matrix with standard of care (SOC) for the treatment of full-thickness Stage III or Stage IV pressure ulcers than when using SOC alone.1 Pressure ulcers are open wounds caused by pressure. They often occur when an individual remains in one position for an extended period.2,3 In the United States, over two million patients are affe
Wed Feb 20, 2019 20:30
SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: Median Technologies (Paris:ALMDT), The Imaging Phenomics Company®, will be participating in the 2019 European Congress of Radiology (ECR), which will take place from February 27th to March 3rd in Vienna, Austria (exhibition dates: Feb 28-March 3). Median will showcase its imaging phenomics platform iBiopsy® at Booth #AI-5, Expo X1 located in the Artificial Intelligence Exhibition Hall. On Feb 28 at 1:40 pm (CET), at the AI Theater (Exp
Wed Feb 20, 2019 18:45
SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News : Median Technologies (Paris:ALMDT), The Imaging Phenomics Company®, participera à l’ECR (European Congress of Radiology) qui se tiendra du 27 Février au 3 Mars 2019 à Vienne (Autriche). L’exposition technique sera ouverte du 28 Février au 3 Mars. Median Technologies y présentera sa plateforme d’imagerie phénomique iBiopsy® sur le stand AI-5 (zone d’exposition X1) localisé dans l’espace exposants dédié à l’Intelligence Artificielle. La
Wed Feb 20, 2019 18:45
CLEVELAND--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/BioMotiv?src=hash" target="_blank"gt;#BioMotivlt;/agt;--Koutif Therapeutics’ IND application has been cleared by FDA to begin a Phase 1 clinical trial for the treatment of IBD.
Wed Feb 20, 2019 18:00
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Professor Diether Lambrechts has received an Agilent Thought Leader Award in support of his research in cancer genomics. Dr. Lambrechts directs the VIB-KU Leuven Center for Cancer Biology in Leuven, Belgium. He is also a professor of human genetics at KU Leuven. Dr. Lambrechts lab focuses on the discovery of genetic or epigenetic markers, either as susceptibility factors for cancer treatment developme
Wed Feb 20, 2019 18:00
DANVERS, Mass.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/heartrecovery?src=hash" target="_blank"gt;#heartrecoverylt;/agt;--Abiomed has now invested more than $100 million over the past five years in clinical research on the Impella heart pump platform.
Wed Feb 20, 2019 15:30
GREENWOOD VILLAGE, Colo.--(BUSINESS WIRE)--PSC Partners Seeking a Cure announced today a partnership with Komodo Health to enhance health outcomes for Primary Sclerosing Cholangitis (PSC) patients. This partnership allows the nonprofit to gain a deeper understanding of referral patterns across institutions and patient flows across systems of care. By utilizing the data garnered from Komodo Health, PSC Partners aims to improve patient care for those afflicted by PSC, while also expanding researc
Wed Feb 20, 2019 15:00
BOSTON--(BUSINESS WIRE)--Cerevel Therapeutics appoints veteran Central Nervous System (CNS) medicines developer Raymond Sanchez, M.D. as chief medical officer
Wed Feb 20, 2019 15:00
HOUSTON--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/MDAR?src=hash" target="_blank"gt;#MDARlt;/agt;--Dacarba LLC, an Opportune LLP company, is pleased to announce that it has launched a proprietary data-driven prescriptive analytics software, Medical Diagnosis Accuracy Reporting (MDAR), which paints an accurate and transparent picture of each patient’s comorbidities for providers and improves quality measurement. The technology solution creates an equal playing field across healthcare...
Wed Feb 20, 2019 15:00
WILMINGTON, N.C. & BEIJING--(BUSINESS WIRE)--PPD and Happy Life Tech of China have signed an exclusive agreement to develop a distinctive service offering for the China drug-development market
Wed Feb 20, 2019 14:00
ST. PAUL, Minn.--(BUSINESS WIRE)--On Wednesday, February 27, 2019, Cardiovascular Systems’ (NASDAQ: CSII) Chairman, President and Chief Executive Officer, Scott Ward, and Chief Operating Officer, Rhonda Robb, will present at the 8th Annual SVB Leerink Global Healthcare Conference at 3:00 p.m. Eastern Time. You may access the live audio webcast, as well as a replay, on the company’s investor relations website, https://investors.csi360.com/events-and-presentations/events-calendar/default.aspx. Ab
Wed Feb 20, 2019 14:00
NEW YORK--(BUSINESS WIRE)--Rocket Pharmaceuticals Announces Participation in Fireside Chat at the 8th Annual SVB Leerink Global Healthcare Conference
Wed Feb 20, 2019 14:00
KENILWORTH, N.J.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24MRK&src=ctag" target="_blank"gt;$MRKlt;/agt; lt;a href="https://twitter.com/hashtag/MRK?src=hash" target="_blank"gt;#MRKlt;/agt;--FDA Grants Priority Review to Merck’s sBLA for KEYTRUDA Monotherapy for Third-Line Treatment of Patients with Advanced Small Cell Lung Cancer
Wed Feb 20, 2019 13:45
IRVINE, Kalifornien--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), ein Medizintechnikunternehmen, das sich auf die Entwicklung und Vermarktung neuartiger, implantierbarer Medizinprodukte zur sakralen Neuromodulation (SNM) spezialisiert hat, die zur Behandlung von Fehlfunktionen des Harn- und Darmtraktes verwendet werden, gab heute erste klinische Ergebnisdaten aus der ARTISAN-SNM-Pivotstudie bekannt, die bei der US-amerikanischen Arzneimittelzulassungsbehörde (Food and
Wed Feb 20, 2019 12:23
IRVINE, Californie--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ : AXNX), une société de technologie médicale spécialisée dans le développement et la commercialisation de nouveaux dispositifs implantables de neuromodulation sacrée (« NMS ») pour le traitement des problèmes de dysfonctionnement urinaire et intestinal, a annoncé aujourd’hui les premiers résultats positifs issus de l’étude pivot ARTISAN-SNM, visant à obtenir l’approbation marketing de la Food & Drug Administr
Wed Feb 20, 2019 12:23
CAMBRIDGE, England--(BUSINESS WIRE)--Cell Mogrify Ltd (Mogrify), a UK company aiming to transform the future development of cell therapies, today announced a second close on its seed funding, bringing the total raised to $3.7 million USD, and the appointment of Darrin M Disley, PhD, DSc, OBE, as CEO. The Company will use the funding to market novel IP and cell types generated using its proprietary direct cellular conversion platform, which will power the development and manufacture of lifesavin
Wed Feb 20, 2019 12:05
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces the publication of a Phase 1a/b study showing the potential of mRNA encoding for VEGF-A as a regenerative therapeutic.
Wed Feb 20, 2019 12:00
英国剑桥和中国上海同步发布--(BUSINESS WIRE)--Owlstone Medical Partners with Shanghai Renji Hospital to Pioneer Breath Biopsy Lung Cancer Trial in China
Wed Feb 20, 2019 11:00
RAINBACH, Austria--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/biomarkers?src=hash" target="_blank"gt;#biomarkerslt;/agt;--GENSPEEDs novel point-of-care testing technology enables rapid test for medical risk classification
Wed Feb 20, 2019 11:00
CAMBRIDGE, England & SHANGHAI, China--(BUSINESS WIRE)--Owlstone Medical Partners with Shanghai Renji Hospital to Pioneer Breath Biopsy Lung Cancer Trial in China
Wed Feb 20, 2019 11:00
KENILWORTH, N.J.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24MRK&src=ctag" target="_blank"gt;$MRKlt;/agt; lt;a href="https://twitter.com/hashtag/MRK?src=hash" target="_blank"gt;#MRKlt;/agt;--Merck Provides Update on KEYNOTE-240, a Phase 3 Study of KEYTRUDA® in Previously Treated Patients with Advanced Hepatocellular Carcinoma
Tue Feb 19, 2019 23:10
OVERLAND PARK, Kan.--(BUSINESS WIRE)--HumanGood and Netsmart have announced a partnership to enhance and integrate the aging experience through a single electronic health record (EHR) platform that spans all senior living care settings and facilities. HumanGood has been recognized in the senior living industry for reinventing the Continuing Care Retirement Community (CCRC) concept, identifying outdated and inefficient care models and replacing them with a seamless aging experience for their res
Tue Feb 19, 2019 21:00
NEW ORLEANS & NEW YORK--(BUSINESS WIRE)--Ochsner Health System, Louisiana’s largest non-profit academic healthcare system, and Pfizer Inc (NYSE:PFE) have entered into a multi-year strategic alliance to develop innovative models for clinical trials. Through this partnership, Pfizer and Ochsner — through its innovation lab, innovationOchsner (iO), in partnership with Ochsner Research — will explore ways to enhance the clinical trial experience and ease participation in clinical research for both
Tue Feb 19, 2019 17:30
IRVINE, California--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), una compañía de tecnología médica centrada en el desarrollo y comercialización de nuevos dispositivos implantables de neuromodulación sacra ("SNM") para el tratamiento de la disfunción urinaria e intestinal, ha revelado hoy unos resultados de primera línea positivos del estudio pivotal ARTISAN-SNM, diseñado para obtener la aprobación de comercialización de la Administración de Alimentos y Medicamentos ("F
Tue Feb 19, 2019 17:18
IRVINE, CALIFORNIË--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), een medisch technologiebedrijf dat zich richt op de ontwikkeling en commercialisering van nieuwe implanteerbare Sacral Neuromodulation (“SNM”)-apparaten voor de behandeling van urinaire- en darmstoornissen, onthulde vandaag positieve resultaten in de top van de ARTISAN-SNM centrale studie, ontworpen om marketinggoedkeuring te verkrijgen van de Amerikaanse Food & Drug Administration (“FDA”) voor het Ax
Tue Feb 19, 2019 17:18
IRVINE, California--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), un’impresa operante nel settore delle tecnologie mediche impegnata nello sviluppo e nella commercializzazione di innovativi dispositivi impiantabili per la neuromodulazione sacrale (NMS) per il trattamento delle disfunzioni della vescica e dell’intestino, ha comunicato oggi i risultati salienti positivi emersi dallo studio principale ARTISAN-SNM, volto all’ottenimento dell’autorizzazione alla commercializ
Tue Feb 19, 2019 17:08
CRANBURY, N.J.--(BUSINESS WIRE)--OncLive® Presents State of the Science Summit™ on Gastrointestinal Malignancies
Tue Feb 19, 2019 16:51
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the European Commission (EC) has approved ZIRABEV™ for the treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer, unresectable advanced, metastatic or recurrent non-small cell lung cancer (NSCLC), advanced and/or metastatic renal cell cancer and persistent, recurrent or metastatic carcinoma of the cervix.1,2 “Pfizer is dedicated to increasing access to biosimilars for patients suffering from serious
Tue Feb 19, 2019 16:32
NEW YORK--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/MDSO?src=hash" target="_blank"gt;#MDSOlt;/agt;--Medidata (NASDAQ: MDSO) today announced its participation in two upcoming investor conferences. Rouven Bergmann, chief financial officer, will present at the Morgan Stanley Technology, Media & Telecom Conference on Wednesday, Feb. 27, 2019, in San Francisco at 2:05 p.m. PT (5:05 p.m. ET). Dr. Bergmann will also present at the 8th Annual SVB Leerink Global Healthcare Conference on...
Tue Feb 19, 2019 15:30
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, announced today that its manuscript titled, “An intra-procedural endoscopic cleansing device for achieving adequate colon preparation in poorly prepped patients,” has been published in the peer-reviewed Journal of Clinical Gastroenterology. The Company’s flagship prod
Tue Feb 19, 2019 15:05
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) today shared additional clinical results from the MoveDMD trial of edasalonexent.
Tue Feb 19, 2019 15:00
NEW YORK--(BUSINESS WIRE)--Ophthotech today announced that it will report its fourth quarter and full year 2018 financial and operating results on Tuesday, February 26, 2019.
Tue Feb 19, 2019 15:00
BOSTON & HAMILTON, Ontario--(BUSINESS WIRE)--Fusion Pharma Announces First Patient Dosing in a Phase 1 Clinical Trial of [225Ac]-FPI-1434 Injection in Patients with Advanced Solid Tumors
Tue Feb 19, 2019 15:00
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου